Venous thromboembolism (VTE) represents a relatively common complication in patients with cancer and is associated with considerable morbidity and mortality as well as resources utilization and health care costs. Cancer confers a 12-fold higher risk of developing VTE within the first 6 months after diagnosis, which is further augmented up to 23-fold during chemotherapy or targeted anti-cancer therapy [1].
